Download PDF
Thromb Haemost 1986; 56(03): 302-307
DOI: 10.1055/s-0038-1661672
Original Article
Schattauer GmbH Stuttgart

Comparative Turn-Over of Heparin Cofactor II and Antithrombin III in Baboons Influence of Heparin and Pentosan Polysulfate Administration

P Sié
1   The Laboratoire d’Hémostase, CRTS, Hôpital Purpan, Toulouse, France
,
J Lansen
2   The Centre de Recherche Clin-Midy-Groupe Sanofi, Montpellier, France
,
F Lacheretz
2   The Centre de Recherche Clin-Midy-Groupe Sanofi, Montpellier, France
,
B Verschuere
2   The Centre de Recherche Clin-Midy-Groupe Sanofi, Montpellier, France
,
B Boneu
1   The Laboratoire d’Hémostase, CRTS, Hôpital Purpan, Toulouse, France
› Author Affiliations
Further Information

Publication History

Received 06 March 1986

Accepted after revision 29 August 1986

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Heparin and pentosan polysulfate (PPS) interact in plasma with antithrombin III (AT III) and Heparin cofactor II (HC II) respectively. To assess the influence of heparin or PPS treatment on the metabolism of their respective cofactors, we performed a double tracer study in baboons receiving heparin or PPS. Purified AT III and HC II from human plasma were labelled with 131I and 125I respectively by the lactoperoxidase-glucose oxidase technique. The tracers had unchanged biological activities, were homogenous in SDS-PAGE, migrated as native proteins by crossed immunoelectrophoresis in the presence of heparin or PPS and virtually coeluted with endogenous baboon proteins from heparin-agarose. Nine animals were randomly allocated to receive, during the metabolic study, heparin (500 IU/kg/d, n = 3), PPS (5 mg/kg,d, n = 3) or a placebo (n = 3) given in 2 daily subcutaneous injections. Heparin levels and anticoagulant effects were similar in extent and duration to those usually achieved in man. The plasma concentrations of AT III and HC II did not vary under treatment. The half-life of the elimination phase in the placebo group ranged from 1.95 to 2.33 d for AT III and from 1.96 to 2.21 d for HC II. There was no significant difference in the half-lives of the 2 inhibitors between the placebo group and the animals receiving heparin or PPS. This suggests that clinical conditions associated with heparin treatment may be important for the effect of heparin on AT III metabolism previously reported in patients. When the data of the nine animals were pooled, a strong positive correlation (p <0.001) between the halflives of AT III and HC II was found, indicating similarities in the catabolic pathways of these two parent molecules.

Keywords

Heparin cofactors - Antithrombin III - Turnover studies - Baboons - Pentosanpolysulfate
 

  • References

  • 1 Briginshaw GF, Shanberge JN. Identification of two distinct heparin cofactors in human plasma. Separation and partial purification. Arch Biochem Biophys 1974; 161: 683-690
    CrossrefPubMedGoogle Scholar
  • 2 Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
    CrossrefPubMedGoogle Scholar
  • 3 Parker KA, Tollefsen DM. The protease specificity of heparin cofactor II. J Biol Chem 1985; 260: 3501-3505
    PubMedGoogle Scholar
  • 4 Church FC, Noyes CM, Griffith MJ. Inhibition of chymotrypsin by heparin cofactor II. Proc Natl Acad Sci USA 1985; 82: 6431-6434
    CrossrefPubMedGoogle Scholar
  • 5 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
    PubMedGoogle Scholar
  • 6 Griffith MJ, Noyes CM, Church FC. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 1985; 260: 2218-2225
    PubMedGoogle Scholar
  • 7 Fair DS, Bahnak BR. Human hepatoma cells secrete single chain factor X, prothrombin, and antithrombin III. Blood 1984; 64: 194-204
    PubMedGoogle Scholar
  • 8 Jaffe EA, Armellino D, Tollefsen DM. Biosynthesis of functionally active heparin cofactor II by a human hepatoma derived cell line. Biochem Biophys Res Commun 1985; 132: 368-374
    CrossrefPubMedGoogle Scholar
  • 9 Sié P, Dupouy D, Pichon J, Boneu B. Turn-over study of heparin cofactor II in healthy man. Thromb Haemostas 1985; 54: 635-638
    PubMedGoogle Scholar
  • 10 Collen D, Schetz J, de Cock F, Holmer E, Verstraete M. Metabolism of antithrombin III (heparin cofactor) in man: Effects of venous thrombosis and of heparin administration. Eur J Clin Invest 1977; 7: 27-35
    CrossrefPubMedGoogle Scholar
  • 11 de Swart CA M, Nijmeyer B, Andersson LO, Holmer E, Sixma JJ, Bouma BN. Elimination of intravenously administered radiolabelled antithrombin III and heparin in humans. Thromb Haemostas 1984; 52: 66-70
    PubMedGoogle Scholar
  • 12 Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; 2: 581-584
    CrossrefPubMedGoogle Scholar
  • 13 Wunderwald P, Schrank WJ, Port H. Antithrombin BM from human plasma: An antithrombin binding moderately to heparin. Thromb Res 1982; 25:: 177-191
    CrossrefPubMedGoogle Scholar
  • 14 Scully MF, Kakkar VV. Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulphate (SP54). Thromb Res 1984; 36: 187-194
    CrossrefPubMedGoogle Scholar
  • 15 Sié P, Dupouy D, Pichon J, Boneu B. Constitutional heparin co-factor II deficiency associated with recurrent thrombosis. Lancet 1985; 2: 414-416
    PubMedGoogle Scholar
  • 16 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169
    PubMedGoogle Scholar
  • 17 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 18 Barrowcliffe TW. Studies of heparin binding to antithrombin III by crossed immunoelectrophoresis. Thrombos Haemostas 1979; 42: 1434-1445
    PubMedGoogle Scholar
  • 19 Murano G, Williams L, Miller-Andersson M, Aronson DL, King C. Some properties of antithrombin-III and its concentration in human plasma. Thromb Res 1980; 18: 259-262
    CrossrefPubMedGoogle Scholar
  • 20 Ceustermans R, Hoylaerts M, de Mol M, Collen D. Preparation, characterization, and turnover properties of heparin-antithrombin III complexes stabilized by covalent bonds. J Biol Chem 1982; 257: 3401-3408
    PubMedGoogle Scholar
  • 21 Marciniak E. Thrombin-induced proteolysis of human antithrombin III: an outstanding contribution of heparin. Br J Haematol 1981; 48: 325-336
    CrossrefPubMedGoogle Scholar
  • 22 Sié P, Ofosu F, Fernandez F, Buchanan MR, Petitous M, Boneu B. Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides. Br J Haematol 1986 (in press)
    PubMedGoogle Scholar
  • 23 Scully MF, Weerasinghe KM, Ellis V, Djazaeri B, Kakkar VV. Anticoagulant and antiheparin activities of a pentosan polysulphate. Thromb Res 1983; 31: 87-97
    CrossrefPubMedGoogle Scholar
  • 24 bis Dol F, Sié P, Dupouy D, Boneu B. Effect of pentosan polysulphate administration in man on the formation of covalent complexes between heparin cofactor II and thrombin generated in plasma by contact activation. Thromb Haemostas 1986; 56: 295-298
    PubMedGoogle Scholar
  • 25 Carlson TH, Atencio AC, Simon TL. Comparison of the behaviour in vivo of two molecular forms of antithrombin III. Biochem J 1985; 225: 557-564
    CrossrefPubMedGoogle Scholar
  • 26 Carlson TH, Simon TL, Atencio AC. In vivo behavior of human radioiodinated antithrombin III: distribution among three physiologic pools. Blood 1985; 66: 13-19
    PubMedGoogle Scholar
  • 27 Chan V, Lai CL, Chan TK. Metabolism of antithrombin III in cirrhosis and carcinoma of the liver. Clin Sci 1981; 60: 681-688
    CrossrefPubMedGoogle Scholar
  • 28 Knot EA R, Ten Cate JW, Drijfhout HR, Kahle LH, Tytgat GN. Antithrombin III metabolism in patients with liver disease. J Clin Pathol 1984; 37: 523-530
    CrossrefPubMedGoogle Scholar
  • 29 Marciniak E, Gockerman JP. Kinetics of elimination of antithrombin III concentrate in heparinized patients. Br J Haematol 1981; 48: 617-625
    PubMedGoogle Scholar
  • 30 Carlson TH, Atencio AC, Simon TL. In vivo behavior of radioiodinated rabbit antithrombin III. Demonstration of a noncirculating vascular compartment. J Clin Invest 1984; 74: 191-199
    CrossrefPubMedGoogle Scholar